Apollo Hospitals is set to enhance its urban footprint through the commissioning of new hospitals, specialised cancer facilities including proton therapy, and the integration of digital and pharmacy services, underlining its strategic growth in high-demand markets.
Apollo Hospitals Enterprise is pressing ahead with a broad expansion plan that includes new company-owned clinics, fresh oncology capacity and a larger bed base across India’s metro markets as it prepares for the next phase of growth. In a statement on its first-quarter FY27 results, founder and chairman Prathap C. Reddy said the group has already commissioned five new hospitals with about 1,000 census beds and expects the remaining capacity to be brought on stream over the next 12 to 18 months.
The company said Apollo Health & Lifestyle plans to open a few owned clinics by the end of FY27, although it has not yet disclosed how many, where they will be located or what services they will offer. The wider pipeline stretches across Chennai, Varanasi, Mumbai, Ranchi, Indore and Delhi, reflecting Apollo’s continued focus on urban markets where demand for specialist healthcare remains strong.
Cancer care is a major part of that strategy. Apollo has outlined a 600-bed Delhi Cancer Centre with proton therapy and a 140-bed comprehensive cancer care facility with proton therapy in Hyderabad. Proton therapy, a highly targeted form of radiation treatment, is considered especially important in complex oncology cases because it can help limit damage to surrounding tissue. The company also said it added about 50 speciality diagnostic tests in the quarter, underscoring the way it is tying diagnostics more closely to hospital-led care.
Apollo’s digital and pharmacy businesses are also set for a structural change. The company said Apollo 24/7, pharmacy and telehealth operations are proposed to be moved into a new entity under a scheme of arrangement, with a stock-market listing targeted for the fourth quarter of FY27, subject to approvals. Moneycontrol reported that the demerger remains on track and that shareholder approval is expected in June, while Apollo is also pursuing wider portfolio reshaping, including the planned combination of its maternity and fertility business with Cloudnine. Analysts and company executives have said the group’s growth plan is being supported by new beds, stronger diagnostics and a push to deepen its presence in high-value specialities.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
